Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Treasury Shares (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Treasury Shares for 11 consecutive years, with $74701.0 as the latest value for Q1 2026.

  • For Q1 2026, Treasury Shares changed N/A year-over-year to $74701.0; the TTM value through Mar 2026 reached $74701.0, changed N/A, while the annual FY2025 figure was $741454.0, N/A changed from the prior year.
  • Treasury Shares hit $74701.0 in Q1 2026 for Crescent Biopharma, down from $741454.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $741454.0 in Q4 2025 and bottomed at $48133.0 in Q3 2024.
  • Average Treasury Shares over 5 years is $193033.1, with a median of $118864.0 recorded in 2025.
  • Year-over-year, Treasury Shares tumbled 63.43% in 2022 and then soared 810.78% in 2025.
  • Crescent Biopharma's Treasury Shares stood at $204785.0 in 2022, then tumbled by 42.79% to $117157.0 in 2023, then plummeted by 58.92% to $48133.0 in 2024, then soared by 1440.43% to $741454.0 in 2025, then plummeted by 89.93% to $74701.0 in 2026.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $74701.0, $741454.0, and $438386.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.